Short answer
Akebia Therapeutics, Inc. (AKBA) filed an 8-K current report with the SEC on August 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q2 2026 results for quarter ended June 30, 2026, announced August 5, 2026.
Akebia Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 2026 results for quarter ended June 30, 2026, announced August 5, 2026
- Recent business highlights included in Exhibit 99.1, the company’s press release
- Investor focus: quarterly financial performance and operating developments disclosed in the attached release
Item EX-99.1 · Exhibit EX-99.1
- Q2 revenue $49.1M, down from $62.5M, as Auryxia fell to $25.5M amid generic competition
- Vafseo revenue $21.3M, up 34% sequentially, with active patients exceeding 10,500 and prescribers reaching approximately 1,200
- Net loss $8.9M versus $0.2M income, including $1.9M restructuring expense and higher commercialization and pipeline costs
- Cash $155.5M at June 30, down from $184.8M at December 31, with refinancing of senior secured debt planned
- VOICE interim analysis showed improved safety versus ESA, while ebribafusp Phase 2 enrollment targets up to 30 patients with initial data expected in 2027
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Akebia Therapeutics, Inc. 8-K filings
Get the next AKBA 8-K as it lands
Follow AKBA for push alerts, or ask the research agent what this filing means.